Lawitz

Sabah Lawitz hikes with her pup quite often and says what her dog does on the trail comes off the trail with her. "I pick it up leave it in a bag and on my way down I throw it in the trash," she said. It is clear, though, she's among a small group of ...

The study was led by Eric Lawitz, MD from the University of Texas Health Science Center in San Antonio. Dr. Lawitz shared the results of his study at the International Liver Congress. The therapy has shown amazing results within six weeks for hepatitis ...

Cure rates with the new agents -- sofosbuvir (Sovaldi), combined with velpatasvir and GS-9857 -- are above 90%, but that means some patients still do not succeed in clearing the virus, according to Eric Lawitz, MD, of the University of Texas Health ...

“As increasing numbers of patients get treated, the number of patients that, cumulatively, will fail will increase over time despite rates of 95% or higher,” Eric Lawitz, MD, of Texas Liver Institute, University of Texas Health Science Centre, San ...

Eric Lawitz of the Texas Liver Institute presented findings from studies of a three-drug regimen consisting of the HCV NS5B polymerase inhibitor sofosbuvir (Sovaldi), the pangenotypic second-generation NS5A inhibitor velpatasvir (formerly GS-5816), and ...